DAFNA Capital Management’s CytomX Therapeutics CTMX Stock Holding History

DAFNA Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.64M	Buy	438,407 +208,407	+91%	+$796K	0.31%	53
2026 Q1	$1.08M	Buy	+230,000	New	+$1.17M	0.25%	58
2020 Q3	–	Sell	-6,100	Closed	-$51K	–	84
2020 Q2	$51K	Sell	6,100 -93,900	-94%	-$872K	0.01%	87
2020 Q1	$767K	Hold	100,000	–	–	0.32%	57
2019 Q4	$831K	Hold	100,000	–	–	0.29%	61
2019 Q3	$738K	Buy	+100,000	New	+$986K	0.28%	64
2017 Q4	–	Sell	-5,900	Closed	-$107K	–	74
2017 Q3	$107K	Buy	+5,900	New	+$92.1K	0.07%	71

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

DAFNA Capital Management's CTMX Position: Q2 2026 in Review

DAFNA Capital Management increased its CytomX Therapeutics (CTMX) stake by 91% in Q2 2026, buying an estimated $796K and bringing the position to 438,407 shares worth $1.64M. The position accounts for 0.31% of the portfolio, ranked #53.

DAFNA Capital Management first reported a position in CTMX in Q3 2017 and has held it in 7 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

DAFNA Capital Management held 438,407 shares of CytomX Therapeutics worth $1.64M as of Q2 2026.
DAFNA Capital Management bought 208,407 CytomX Therapeutics shares in Q2 2026, an estimated $796K.
CytomX Therapeutics made up 0.31% of DAFNA Capital Management's portfolio in Q2 2026, its #53 holding.
DAFNA Capital Management first reported a position in CytomX Therapeutics in Q3 2017 and has held it in 7 quarters since.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.